Berinert is a human plasma-derived C1 Esterase Inhibitor indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients

Pre-Authorization Criteria: treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adults and adolescent

**Dosing** (adult and adolescent):

- **Prophylaxis**: 1000 units IV every 3-4 days
- **Acute episodes**: 20 units/kg IV

**PRECAUTIONS**: headache/dizziness; nausea/vomiting; rash/pruritis; flu-like symptoms; injection site irritation; hypersensitivity/anaphylaxis (rare); thrombosis

**DRUG INTERACTIONS**: androgens, estrogens or progestins could enhance the thrombogenic effect

**REFERENCES**


**Revision History:**

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/22/13</td>
<td>Yes</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/21/13</td>
<td>Yes</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/20/13</td>
<td>Yes</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>